These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37929314)

  • 1. Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review.
    Moshegov S; Kerr NM
    Expert Opin Investig Drugs; 2023; 32(11):1017-1023. PubMed ID: 37929314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
    Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
    Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma.
    Matsou A; Anastasopoulos E
    Expert Opin Investig Drugs; 2018 Oct; 27(10):777-785. PubMed ID: 30227753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.
    Impagnatiello F; Bastia E; Almirante N; Brambilla S; Duquesroix B; Kothe AC; Bergamini MVW
    Br J Pharmacol; 2019 Apr; 176(8):1079-1089. PubMed ID: 29669171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
    Fingeret M; Gaddie IB; Bloomenstein M
    Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
    Angeli A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
    [No Abstract]   [Full Text] [Related]  

  • 9. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
    Araie M; Sforzolini BS; Vittitow J; Weinreb RN
    Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
    Wirta DL; Kuwayama Y; Lu F; Shao H; Odani-Kawabata N
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):240-251. PubMed ID: 35167779
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
    Tanna AP; Lin AB
    Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors.
    Lusthaus JA; Goldberg I
    Expert Opin Emerg Drugs; 2016; 21(1):117-28. PubMed ID: 26854598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
    Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
    Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.
    Berlin MS; Rowe-Rendleman C; Ahmed I; Ross DT; Fujii A; Ouchi T; Quach C; Wood A; Ward CL
    Br J Ophthalmol; 2016 Jun; 100(6):843-7. PubMed ID: 26453641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
    Holló G; Topouzis F; Fechtner RD
    Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma.
    Wang Y; Liao Y; Nie X
    Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
    Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
    Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.